ArthroCare

Jefferies & Company has raised the price target on ArthroCare (NASDAQ: ARTC) from $36 to $37 and maintains its Buy rating.

Jefferies & Company has raised the price target on ArthroCare (NASDAQ: ARTC) from $36 to $37 and maintains its Buy rating.

ArthroCare Corp. (NASDAQ: ARTC), a leader in developing state-of-the-art, minimally invasive surgical products, announced today it will present during the UBS Global Life Sciences Conference. Todd Newton, Senior Vice President and CFO of ArthroCare, will deliver the business presentation. Please...

ArthroCare (NASDAQ: ARTC) released 2Q revenue numbers of $88.8 vs. Jefferies estimate of $86.7, with softer margins than expected but ARTC has done maintenance on its finances, allowing it to report EPS of $0.22, $0.06 higher than estimates. Jefferies maintains its "buy" rating and price target of...